Nice work: 200% growth Q1

Posted 19 May 2022 PM

Companies that market vaccines and therapies to combat Covid continued to lead revenue growth in the first quarter of 2022, however investor interest is declining.

Twelve of the industry's top 23 companies achieved double-digit growth, with the top five - all fuelled by sales of Covid products - each surpassing a 50 per cent revenue increase compared with the first quarter of last year.

To see the whole article, please login